NL7307313A - - Google Patents

Info

Publication number
NL7307313A
NL7307313A NL7307313A NL7307313A NL7307313A NL 7307313 A NL7307313 A NL 7307313A NL 7307313 A NL7307313 A NL 7307313A NL 7307313 A NL7307313 A NL 7307313A NL 7307313 A NL7307313 A NL 7307313A
Authority
NL
Netherlands
Application number
NL7307313A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7307313A publication Critical patent/NL7307313A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/86Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
NL7307313A 1972-05-25 1973-05-25 NL7307313A (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19722226703 DE2226703A1 (de) 1972-05-25 1972-05-25 Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
NL7307313A true NL7307313A (cs) 1973-11-27

Family

ID=5846530

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7307313A NL7307313A (cs) 1972-05-25 1973-05-25

Country Status (12)

Country Link
JP (1) JPS4941367A (cs)
AT (1) AT323155B (cs)
AU (1) AU5607873A (cs)
BE (1) BE800066A (cs)
CA (1) CA1005062A (cs)
CH (1) CH582144A5 (cs)
CS (1) CS179416B2 (cs)
DD (1) DD106170A5 (cs)
DE (1) DE2226703A1 (cs)
FR (1) FR2185414B1 (cs)
GB (1) GB1436893A (cs)
NL (1) NL7307313A (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235903A (en) * 1979-08-06 1980-11-25 American Home Products Corporation 1-Hydroxyalkanamine tetrahydrocarbazoles and cyclopent[b]indoles, compositions and method of use
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
US7211599B2 (en) 2002-09-19 2007-05-01 The Regents Of The University Of California Use of etodolac to treat hyperplasia
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
CA2538759C (en) * 2003-09-12 2015-11-03 Elixir Pharmaceuticals, Inc. Substituted heterocyclic compounds as sirtuin inhitibitors
MXPA06003758A (es) 2003-10-02 2006-08-11 Cephalon Inc Derivados de indol substituido.
DK2326621T3 (en) * 2008-07-23 2016-09-12 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-yl acetic acid derivatives suitable for the treatment of autoimmune and inflammatory disorders
BRPI0917923B1 (pt) 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011109471A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
MX2020013157A (es) 2018-06-06 2021-04-29 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
CN114634442B (zh) * 2022-04-02 2023-10-13 内蒙古民族大学 一种四氢咔唑酮化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH586678A5 (cs) * 1970-05-25 1977-04-15 Hoffmann La Roche
ZA715217B (en) * 1970-08-20 1972-04-26 Org Nv Anti-inflammatory preparations

Also Published As

Publication number Publication date
AU5607873A (en) 1974-11-28
CS179416B2 (en) 1977-10-31
CA1005062A (en) 1977-02-08
BE800066A (fr) 1973-11-26
FR2185414A1 (cs) 1974-01-04
GB1436893A (en) 1976-05-26
DE2226703A1 (de) 1973-12-13
JPS4941367A (cs) 1974-04-18
CH582144A5 (cs) 1976-11-30
FR2185414B1 (cs) 1976-08-13
AT323155B (de) 1975-06-25
DD106170A5 (cs) 1974-06-05

Similar Documents

Publication Publication Date Title
JPS5219481B2 (cs)
FR2185414B1 (cs)
JPS5716019B2 (cs)
JPS517426B2 (cs)
JPS4898942U (cs)
JPS4934237U (cs)
FR2202318B1 (cs)
FR2202832B1 (cs)
JPS48104210A (cs)
JPS4967795A (cs)
JPS493562A (cs)
JPS5154230Y2 (cs)
CS154091B1 (cs)
JPS4965713A (cs)
JPS4995888U (cs)
CS153161B1 (cs)
CS153165B1 (cs)
JPS4889806A (cs)
CS153169B1 (cs)
JPS48103740U (cs)
CS153286B1 (cs)
JPS4930092A (cs)
CS153623B1 (cs)
CH606304A5 (cs)
BG18809A1 (cs)

Legal Events

Date Code Title Description
BV The patent application has lapsed